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Abstract The loss of muscle mass and function with
age, termed sarcopenia, is an inevitable process, which
has a significant impact on quality of life. During
ageing we observe a progressive loss of total muscle
fibres and a reduction in cross-sectional area of the
remaining fibres, resulting in a significant reduction in
force output. The mechanisms which underpin sar-
copenia are complex and poorly understood, ranging
from inflammation, dysregulation of protein metabo-
lism and denervation. However, there is significant
evidence to demonstrate that modified ROS genera-
tion, redox dis-homeostasis and mitochondrial dys-
function may have an important role to play. Based on
this, significant interest and research has interrogated
potential ROS-targeted therapies, ranging from nutri-
tional-based interventions such as vitamin E/C,
polyphenols (resveratrol) and targeted pharmacolog-
ical compounds, using molecules such as SS-31 and
MitoQ. In this review we evaluate these approaches to
target aberrant age-related ROS generation and the
impact on muscle mass and function.
Keywords Sarcopenia  Reactive oxygen species 
Oxidative stress  Mitochondria  Ageing
Introduction
The age-related decline in muscle mass, strength and
function, termed sarcopenia, is a significant contrib-
utor to frailty (Lexell 1993). Approximately 600
million people over the age of 60 years old suffering
from sarcopenia in 2000 and by 2050 this population is
estimated to grow to 2 billion people (Dhillon and
Hasni 2017). Sarcopenia contributes considerably to
the frailty seen in the elderly population, with
sarcopenia being associated with generalised weak-
ness, impaired mobility, poor balance and stamina
(Walston 2012). Consequently, this can lead to an
increasing number of falls, disability and mortality
(Cruz-Jentoft et al. 2014).
Loss of muscle mass typically begins from around
50 years of age, occurring at a rate of around 1–2% per
year, with around a 50% reduction by 80 years of age
(Lexell 1993). Ageing muscle displays a reduction
(atrophy) in overall fibre cross-sectional area, with a
predominant loss of type II muscle fibres (Lexell
1993). Consequently, this results in an overall slow
twitch phenotype, characterised by a reduction in force
generation and activation velocity (Nilwik et al. 2013).
The impact of sarcopenia is compounded via
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unloading and disuse of muscle as a consequence of a
progressively sedentary lifestyle (Breen et al. 2013).
The mechanisms that underpin sarcopenia are not
fully understood, however, it is a complex multifac-
torial network of interacting dysfunctional systems.
Specifically, modified protein synthesis (Breen and
Phillips 2013) and anabolic blunting (Cuthbertson
et al. 2005), alongside chronic low-grade inflamma-
tion (Roubenoff 2003), mitochondrial dysfunction
(Sakellariou et al. 2017), aberrant ROS generation
(Vasilaki and Jackson 2013), denervation (Pollock
et al. 2017; Scalabrin et al. 2019) and a reduced
regenerative capacity (Almada andWagers 2016) are
some of the key processes implicated in sarcopenia. In
this review we will evaluate the ROS generation in
skeletal muscle and the role these processes play in
sarcopenia and current avenues for therapeutic
intervention.
Reactive oxygen and nitrogen species (RONS)
generation and regulation in skeletal muscle
Reactive oxygen and nitrogen species are radical and
non-radical bi products of cellular respiration, formed
via the molecular reduction of atmospheric oxygen.
Skeletal muscle as an excitable tissue with a high
energetic demand is widely described as a significant
generator of RONS. In the context of ageing, seminal
studies in the 1950’s developed the field and investi-
gation of RONS, formulating the ‘‘free radical theory
of ageing’’ (Gerschmann 1954; Haraan 1955). An
increased activity of reactive oxygen species (ROS)
has been implicated in the processes underlying
ageing and, in all species, tissues (including skeletal
muscle) of aged organisms contain increased amounts
of oxidative damage to lipids, DNA and proteins
(Vasilaki et al. 2006).
There are a diverse family of RONS in skeletal
muscle, with superoxide (O2.
-) and nitric oxide
(NO-) are the primary species generated at rest and
in response to contractile activity (Sakellariou et al.
2014). Moreover, there is a complex network of
enzymatic and non-enzymatic antioxidant defence
mechanisms which regulate RONS generation (Halli-
well and Guttridge 2015).
Superoxide is generated from complex I, II and III
of the electron transport chain and the nicotinamide
adenine dinucleotide phosphate NAD(P)H oxidases,
xanthine oxidase and lipoxygenase enzymes (Hellsten
et al. 1997; Zuo et al. 2004; Muller et al. 2004;
Goncalves et al. 2015). Superoxide has a relatively
long biological half-life of * 10-6 s, is membrane
impermeable, bar movement via specific membrane
channels (TOM40/VDAC/BAX). Superoxide has a
low oxidising capacity towards cellular macro-
molecules; however, it may react with other species
such as NO-, forming the highly reactive peroxyni-
trite (ONOO-) (Halliwell and Guttridge 2015). Typ-
ically, superoxide is dismutated to hydrogen peroxide
(H2O2) by the superoxide dismutase (SOD) family of
enzymes (Fukai and Ushio-Fukai 2011). The SOD
family of enzymes are characterised by their ability to
convert O2.
- to H2O2 are localised to different cellular
compartments and differentiated by the transition
metal bound to the active site. SOD1 termed
CuZnSOD is localised to both the cytosol and
mitochondrial intermembrane space; SOD2 termed
MnSOD is enriched within the mitochondrial matrix
and SOD3 (extracellular SOD) has a CuZn cofactor
and is found in the interstitial spaces (Halliwell and
Guttridge 2015). Approximately 35% of all cellular
SOD activity is localised to the mitochondria to
skeletal muscle (Ji et al. 1998). Modification of SOD
activity and function has been shown to induce
dysfunction in skeletal muscle. Specifically, SOD1
gene knockout mice display elevated markers of
oxidative damage and an overall accelerated sar-
copenic phenotype and is a model for amyotrophic
lateral sclerosis (Deepa et al. 2019). In response to
contractile activity, skeletal muscle upregulates the
expression of both SOD1 and 2, with a higher activity
in type I slow oxidative muscle fibres (Kojda and
Hambrecht 2005).
Nitric oxide (NO-) is generated by the nitric oxide
synthase (NOS) enzymes, catalysing the conversion of
L-arginine to citrulline (Korhonen et al. 2005). NO-
has a biological half-life of* 1–10-1 s and functions
via s-nitrosylation of cysteine residues (Stamler and
Meissner 2001). There are three key members of the
NOS enzyme family: inducible (iNOS), neuronal
(nNOS) and endothelial (eNOS). NO- has a well-
established function in vasodilation and the immune
response and has an important role in muscle physi-
ology. A recent study using the nNOS-/- mouse,
demonstrated NO- helps to regulate muscle fibre type,
fatiguability and post-exercise recovery (Moon et al.
2017). NO- levels are elevated in the muscle fibres of
old mice following contractile activity, associated in
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with elevated marked of nitrosylation (3-nitrotry-
rosine) and eNOS activity (Pearson et al. 2015).
Hydrogen peroxide is a non-radical species, gener-
ated from dismutation of superoxide by the SODs, and
as a bi product of protein folding in the endoplasmic
reticulum via the thiol-disulphide exchange mecha-
nism (Hudson et al. 2015). Comparative to other
radical RONS species, H2O2 has a relatively long half-
life 10-5 s and is membrane permeable. H2O2 levels
are regulated by the enzymes catalase, glutathione
peroxidase (Gpx) and the peroxiredoxin (PRXs)
family, converting it to water and oxygen. Elevated
H2O2 generation has been observed in the muscle of
old mice and is reported to be derived from increased
mitochondria superoxide generation (Mansouri et al.
2006). Moreover, H2O2 has been heavily implicated as
an important mediator of muscle ageing, based on
several studies of the transgenic mCAT model, which
overexpress the human form of catalase in the
mitochondria (Basisty et al. 2016). mCAT mice have
been shown to have increased longevity (Schriner
et al. 2005) and improved muscle function—the latter
due to decreased ca2? leakage from the sarcoplasmic
reticulum (Umanskaya et al. 2014).
Peroxynitrite (ONOO-) is a highly reactive radical
species, formed via the reaction between superoxide
and nitric oxide, with a half-life of 10-2 s. Thiol (-SH)
groups are highly sensitive to peroxynitrite (resulting
in disulphide formation), which can rapidly deplete the
overall thiol pools within the cell. Peroxynitrite
induces the nitration of tyrosine and S-nitrosylation
of cysteine residues and can induce significant damage
to DNA and in some instances, affect enzyme activity
and supress signalling cascades. Studies in isolated
muscle fibres have demonstrated that peroxynitrite
directly suppresses ca2? stimulated force generation
(Dutka et al. 2011). Studies of old mice (26–28 month)
and in the SOD1-/- model have shown a three-fold
increase in 3-nitrotyrosine (3-NT) residues compared
with young/WT controls (Sakellariou et al. 2011;
Pearson et al. 2015).
Hydroxyl radical (OH-) is a highly reactive
species, with a very short half-life * 10-9 s. The
hydroxyl radical is formed via the fenton reaction:
Fe2þ þ H2O2 ! Fe3þ þ OH  þOH
Transition metals such as iron (Fe?) or copper
(Cu2?) can reduce H2O2 to the hydroxyl radical.
Contracting skeletal muscle has been shown to
generate the hydroxyl radical (O’Neill et al. 1996)
and it has been reported to modify calcium sensitivity
and force generation in rodent muscle fibres (Murphy
et al. 2008). However, there are some elements of
controversy in terms of the fenton reaction, given the
relatively low concentrations of transition metals
detected in vivo (Halliwell and Guttridge 2015).
Mitochondrial dysfunction in skeletal muscle
ageing
Skeletal muscle is richly abundant in mitochondria,
due to the high energetic demand of contractile
activity. Thus, given the role of mitochondria in
ROS generation, there has been significant interest in
understanding what if any part mitochondria may play
in muscle wasting and dysfunction. Aberrant ROS
generation and oxidative damage have been associated
with many aspects of mitochondrial dysfunction in
skeletal muscle ageing. Firstly, accumulation of
mitochondrial DNA mutations (mtDNA) in human
aged skeletal muscle is evident (Bua et al. 2006;
Herbst et al. 2007; Melov et al. 1995). Various in vitro
studies have shown association with mtDNA muta-
tions and with reduced content of the etc. complexes,
oxidative phosphorylation, and membrane potential
(Hiona et al. 2010; Sahu et al. 2018), as well as
increased expression of mitochondrial markers of
oxidative damage, decreased antioxidant defense
system and mitochondrial biogenesis, indicative to a
defective adaptive response to mitochondrial dysfunc-
tion in mtDNA mutator mice (Kolesar et al. 2014).
These studies are consistent with results in aged rats
that showed reduced levels of mitochondrial biogen-
esis and function markers, accompanying with swol-
len mitochondria (Zhu et al. 2019; Sahu et al. 2018).
Furthermore, there is an age-related decline in mito-
fusin 2 (Mfn2) a key regulator of mitochondrial fusion
(Sebastian et al. 2016), which an important process
which helps regulate and accommodate the energetic
demands of the cell. Moreover, ablation of Mfn2 in
mice induced an ageing phenotype, associated with
impaired mitophagy (Sebastian et al. 2016). The latter
observation may be related the accumulation of
damaged mitochondria during ageing. Changes have
been observed in both intermyofibrillar (IMF) and
subsarcolemmal (SS) mitochondria in aged mice. IMF
mitochondria appeared longitudinal and branched in
shape, whereas SS mitochondria had a larger and less
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circular appearance—in, contrast they did not observe
changes in absolute Mfn2 levels. However, there was
alteration in the ratio of genes which regulate mito-
chondrial fusion, fission and biogenesis—suggesting
dysregulation of the overall system (Leduc-Gaudet
et al. 2015). Further rodent studies have also demon-
strated ageing and the loss of muscle mass and
function to be associated with a downregulation of
genes encoding key mitochondrial function (Ibebunjo
et al. 2013).
Targeting RONS to combat sarcopenia
Given the ever-ageing population and the socioeco-
nomic impact of sarcopenia, there is an urgent need to
develop effective targeted therapies. Moreover, the
significant evidence of aberrant RONS generation and
mitochondrial dysfunction in muscle ageing suggest
that therapies to target these processes are worthy of
investigation.
Vitamins
Nutritional antioxidants are considered as a potential
approach in an effort to combat the age-related loss of
muscle mass and function, due to their antioxidant and
anti-inflammatory activity. A study showed that both
Vitamin E and C supplementation could improve
muscle function by increasing antioxidant activity and
preventing oxidative stress in aged rats (Ryan et al.
2010). A further insight into the effects of the two
subgroups of vitamin E, tocopherol and tocotrienols,
suggested that both a-tocopherol and tocotrienol-rich
fraction (TRF) can encourage myogenic differentia-
tion during replicative senescence, with TRF having
superior effects (Khor et al. 2016). Data demonstrated
that TRF can promote muscle regeneration during
oxidative stress-induced premature senescence, by
both increasing the proliferation capacity of myoblasts
and maintaining the renewal of satellite cells (Lim
et al. 2019). A further study using a vitamin E analog,
TROLOX, showed that it could prevent oxidative
stress and maintain skeletal muscle mass in an animal
ageing model with muscle specific Opa1 deletion
(Tezze et al. 2017). A clinical trial on female athletes
has shown that supplementation of Vitamin E and C
together or Vitamin C alone could reduce muscle
damage, alongside with decreased levels of oxidative
stress markers, induced by aerobic exercise (Taghiyar
et al. 2013). Further enhancing previous evidence of
beneficial effects of vitamins supplementation in
muscle ageing, a recent study showed a positive
association between high dietary intake of vitamin E,
C, and carotenoids with improved sarcopenic indices
(muscle mass and power); however, this association
was only noticeable in women younger than 65 years
(Welch et al. 2019).
However, it is important to note that there is
compelling evidence demonstrating the use of broad-
spectrum antioxidants such as vitamin C and E, can in
fact suppress the beneficial adaptations in response to
exercise training (Ristow et al. 2009). In contrast,
mitoQ supplementation during endurance training,
displayed no tangible beneficial or negative effects in
terms of adaptations (Shill et al. 2016). Moreover n-
acetylecysteine supplementation has been reported to
suppress fatigue following repeated bouts of intermit-
tent exercise (Cobley et al. 2011). However, RONS are
no longer considered to be purely toxic/damaging
molecules and instead are important mediators and
regulators of an array of signalling cascades and
pathways (Cobley et al. 2015).
Resveratrol
Resveratol has been widely studying in muscle ageing
due to its antioxidant activity, as well as its effects on
peroxisome proliferator-activated receptor gamma
coactivator-1a, an important regulator of mitochon-
drial biogenesis (Gu¨lc¸in 2010). The anti-ageing effects
of resveratrol supplementation for 4 weeks, have been
recently reported, highlighting its capability of inhibit-
ing lipid peroxidation and increasing catalase and
superoxide dismutase activity, by targeting mitochon-
drial mass and function, associated with improved
physical endurance in aged mice (Muhammad and
Allam 2018). In an in vitro study, resveratrol has
shown dose-dependent effects on muscle cell plastic-
ity, with low doses preventing ROS generation and
inducing muscle regeneration, effects not observed in
high doses (Bosutti and Degens 2015). However,
various studies have obtained controversial results on
the effect of resveratrol on ageing-associated muscle
dysfunction. A 6–7-week low-to-moderate daily
resveratrol intake has produced no effects in muscular
strength and function in aged mice (Baumann et al.
2014; Zhou et al. 2019). Similarly, long-term (10
months) low-to-moderate daily resveratrol intake,
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even though it could mitigate ageing-induced oxida-
tive stress, no beneficial effects were observed on
muscle mass and function in aged mice, while
mitochondrial biogenesis was also unaffected by
resveratrol (Park et al. 2018). Overall, it seems that
resveratrol has protective effects against ageing-
induced abnormalities, even the incongruent findings,
as they can likely be explained by variations in the age
of experimental species, as well as the dosage and
duration of supplementation; those variations high-
light the need for further investigation for acute and
chronic resveratrol intake both in vitro and in vivo
with consistent experimental approach.
Targeted antioxidant therapies
When evaluating studies of antioxidants, there is a
large degree of heterogeneity in terms of efficacy and
outcomes. This is likely due in part to a poor
distribution and uptake of such compounds into cells
and tissues, resulting in the need to administer such
antioxidants in high concentrations. In the case of the
latter, this may be a reason for the observed pro-
oxidant effect of some purported antioxidants (Pear-
son et al. 2006). Thus, development of targeted
antioxidant therapies has provided a novel and
promising avenue of research, in an effort to combat
the pitfalls of broad-spectrum approaches.
Given the aforementioned potential role of mito-
chondrial dysfunction in sarcopenia, the use of novel
antioxidant compounds to this organelle have been
investigated in sarcopenia and a range of myopathies
and neuromuscular disease (Sakellariou et al. 2017).
The Szeto-Schiller (SS-) peptide family are small
molecules, with potent antioxidant capacity towards a
range of radical species (Lightfoot et al. 2015). The
Dmt-D-Arg-Phe-atnDAP-NH2 structure of the SS-
peptides results in their accumulation at the inner
mitochondrial membrane (IMM). The accumulation
of SS- peptides at the IMM does not rely on the
mitochondrial membrane potential, which offers a
unique opportunity to target mitochondria which may
have underlying damage (Zhao et al. 2004).
SS-31 has been explored as a potential therapy
against the age-related loss of muscle mass and
function (sarcopenia). Modified ROS generation and
oxidative damage has been widely characterised as an
important mediator of muscle wasting and dysfunction
(Lightfoot et al. 2014). In this study, mice were
administered sub-cutaneous SS-31 peptide (1.5 mg/
kg), over a four-month period from 24 to 28 months of
age. Data showed significant reductions in markers of
oxidative damage in the muscles of old mice, however,
this did prevent the age-related loss of muscle mass
and function (Sakellariou et al. 2016a). This clearly
supports the potent ability of SS peptides as antiox-
idants, however, the lack of change in underlying
pathology in this instance may be due to the complex
and multi-factorial nature of sarcopenia. In contrast,
8-weeks of SS-31 (3 mg/kg) treatment in 26-month old
mice, showed improvements in mitochondrial struc-
ture, function and homeostasisalongside an increased
in exercise tolerance (Campbell et al. 2019). More-
over, short-term (1-h) SS-31 treatment (3 mg/kg) of
27-month-old mice, improved mitochondrial function
and muscle performance (Siegel et al. 2013). Thus,
differences in dose and duration of treatment with SS-
31 in these models may be significant factors in the
observed differences in outcome.
More recently, SS-31 has been explored in the
context of a murine model of doxorubicin-induced
toxicity (Montalvo et al. 2019). Doxorubicin is a
highly potent chemotherapy agent, which has signif-
icant side-effects on muscle. In this study, SS-31 (3
mg/kg) attenuated mitochondrial ROS generation and
proteolytic pathway activity in the muscles of dox-
orubicin treated mice (Montalvo et al. 2019). Further-
more, studies of leukocytes taken from patients with
type 2 diabetes, demonstrated a reduction in inflam-
mation, via down regulation of TNF-alpha and NF-kB
and upregulation of SIRT1, in response to treatment
with SS-31 peptide (Escribano-Lopez et al. 2018).
Thus, there are clear and compelling evidence demon-
strating the potent antioxidant ability of SS family of
peptides in a range of disorders, which can have direct
functional effects.
Mitoquinone is a compound derived from ubiqui-
none, which has a lipophilic cation (triphenylphos-
phonium) conjugated to it, which drives accumulation
of the molecule within mitochondria (Murphy and
Smith 2007). Ubiquione is a crucial component of the
electron transport chain as a two-electron carrier, as
well as having antioxidant capacity (Nicholls and
Ferguson 2002). MitoQ readily accumulates within
the cytosol of the cell driven by the plasma membrane
potential, however, is found in [ 100-fold greater
concentration within the mitochondria at the matrix
face of the inner membrane, driven by the
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mitochondrial membrane potential (Murphy and
Smith 2007). Upon accumulation in the mitochondria,
MitoQ is converted to its active antioxidant form
(ubiquinol) via reduction at complex II (Murphy and
Smith 2007). When acting as an antioxidant, MitoQ is
oxidised to ubiquinone and then rapidly reduced back
to ubiquinol, rejuvenating its antioxidant capacity and
thus, is a marker of the efficacy of MitoQ. MitoQ has
an affinity for an targets the hydroxyl (.OH) radical,
thus preventing lipid peroxidation (Tauskela 2007),
alongside quenching superoxide generation (James
et al. 2005). In the context of ageing-induced
mitochondrial dysfunction, a recent study has clearly
found that MitoQ was able to alleviate ageing-induced
changes in respiratory chain, ATP production, and
membrane potential, highlighting the role of perox-
ynitrite in ageing deficits (Maiti et al. 2018). However,
its effects on ageing-induced muscle atrophy seem to
be less clear. A study of ageing mice (24–26 months)
reported failure of long-term MitoQ supplementation
to protect against age-related loss of muscle mass
function and oxidative damage (Sakellariou et al.
2016b). A further novel mitochondria-targeted antiox-
idant is XJB-5-131, which is TEMPO derivative that
has a gramicidin S moiety conjugated to it, which
encourages accumulation in the mitochondria (Robin-
son et al. 2018). XJB-5-131 has been found to decrease
mitochondrial ROS and membrane depolarization
(Escobales et al. 2014), increase the activity of the
electron transport chain complexes, and improve the
single fibre contractile properties in aged rats (Javadov
et al. 2015).
Conclusions
Aberrant ROS generation and redox dis-homeostasis
have clear and important role to play in the age-related
loss of muscle mass and function (Fig. 1). However,
there is no clear consensus on intervention to target
ROS. There remains significant discordance in find-
ings, likely due to differences in model systems
(species) in tandem with dosing regimens. Moreover,
this raises questions on the ability to translate these
mechanistic findings to humans—where there is a
need to pursue this line of research further.
Open Access This article is licensed under a Creative
Commons Attribution 4.0 International License, which
permits use, sharing, adaptation, distribution and reproduction
in any medium or format, as long as you give appropriate credit
to the original author(s) and the source, provide a link to the
Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are
Fig. 1 A schematic summary of the role of ROS and putative interventions in the age-related loss of muscle mass and function
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